Search Results
You are looking at 1 - 1 of 1 items for
- Author: Toshifumi Takahashi x
- Refine by access: Content accessible to me x
Search for other papers by Botao Du in
Google Scholar
PubMed
Search for other papers by Masahide Ohmichi in
Google Scholar
PubMed
Search for other papers by Kazuhiro Takahashi in
Google Scholar
PubMed
Search for other papers by Jun Kawagoe in
Google Scholar
PubMed
Search for other papers by Chika Ohshima in
Google Scholar
PubMed
Search for other papers by Hideki Igarashi in
Google Scholar
PubMed
Search for other papers by Akiko Mori-Abe in
Google Scholar
PubMed
Search for other papers by Maki Saitoh in
Google Scholar
PubMed
Search for other papers by Tsuyoshi Ohta in
Google Scholar
PubMed
Search for other papers by Akira Ohishi in
Google Scholar
PubMed
Search for other papers by Masakazu Doshida in
Google Scholar
PubMed
Search for other papers by Naohiro Tezuka in
Google Scholar
PubMed
Search for other papers by Toshifumi Takahashi in
Google Scholar
PubMed
Search for other papers by Hirohisa Kurachi in
Google Scholar
PubMed
Although estrogen is known to protect against β-amyloid (Aβ)-induced neurotoxicity, the mechanisms responsible for this effect are only beginning to be elucidated. In addition, the effect of raloxifene on Aβ-induced neuro-toxicity remains unknown. Here we investigated whether raloxifene exhibits similar neuro-protective effects to estrogen against Aβ-induced neurotoxicity and the mechanism of the effects of these agents in PC12 cells transfected with the full-length human estrogen receptor (ER) α gene (PCER). Raloxifene, like 17β-estradiol (E2), significantly inhibited Aβ-induced apoptosis in PCER cells, but not in a control line of cells transfected with vector DNA alone (PCCON). Since telomerase activity, the level of which is modulated by regulation of telomerase catalytic subunit (TERT) at both the transcriptional and post-transcriptional levels, is known to be involved in suppressing apoptosis in neurons, we examined the effect of E2 and raloxifene on telomerase activity. Although both E2 and raloxifene induced telomerase activity in PCER cells, but not in PCCON cells, treated with Aβ, they had no effect on the level of TERT expression. These results suggest that neither E2 nor raloxifene affects the telomerase activity at the transcriptional level. We therefore studied the mechanism by which E2 and raloxifene induce the telomerase activity at the post-transcriptional level. Both E2 and raloxifene induced the phosphorylation of Akt, and pre-treatment with a phosphatidylinositol 3-kinase inhibitor, LY294002, attenuated both E2 − and raloxifene-induced activation of the telomerase activity. Moreover, both E2 and raloxifene induced both the phosphorylation of TERT at a putative Akt phosphorylation site and the association of nuclear factor κB with TERT. Our findings suggest that and raloxifene exert neuroprotective effects by E2 telomerase activation via a post-transcriptional cascade in an experimental model relevant to Alzheimer’s disease.
